|1.||Genovese, Mark C: 5 articles (12/2015 - 02/2011)|
|2.||Weinblatt, Michael E: 5 articles (12/2014 - 02/2011)|
|3.||Kavanaugh, Arthur: 4 articles (12/2014 - 02/2011)|
|4.||Grossbard, Elliott B: 4 articles (07/2013 - 02/2011)|
|5.||Vencovsky, Jiri: 2 articles (12/2015 - 11/2014)|
|6.||Ho, Meilien: 2 articles (12/2015 - 12/2014)|
|7.||Martin, Paul: 2 articles (12/2015 - 12/2014)|
|8.||Can, Guray: 2 articles (10/2015 - 07/2015)|
|9.||Ayvaz, Suleyman: 2 articles (10/2015 - 07/2015)|
|10.||Karaca, Turan: 2 articles (10/2015 - 07/2015)|
11/01/2014 - "The OSKIRA-ambulatory BP monitoring trial assessed the effect of fostamatinib on 24-hour ambulatory systolic BP (SBP) in patients with active rheumatoid arthritis. "
11/01/2014 - "Clinical trials of fostamatinib in patients with rheumatoid arthritis showed blood pressure (BP) elevation using clinic measurements. "
12/01/2014 - "Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib."
09/01/2012 - "Fostamatinib may have a role in the therapy of patients with rheumatoid arthritis with poor response to conventional therapy. "
09/01/2012 - "The status of fostamatinib in the treatment of rheumatoid arthritis."
01/01/2015 - "Fostamatinib, a small molecule SYK inhibitor, has shown evidence of ameliorating inflammation in RA patients. "
07/01/2015 - "Mice treated with fostamatinib also displayed less fibrosis and inflammation in the lung tissue. "
07/01/2015 - "The Syk inhibitor fostamatinib prevented bleomycin-induced fibrosis and inflammation in the skin and in the lung. "
09/01/2011 - "The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice."
03/01/2009 - "Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. "
10/01/2015 - "The study included 28 male Sprague-Dawley rats, randomly divided into control group, fostamatinib group, colitis group and fostamatinib + colitis group, each containing seven rats. "
10/01/2015 - "Fostamatinib reduced the inflammatory damage in the experimental colitis. "
10/01/2015 - "The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis."
10/01/2015 - "The disease activity index, macroscopic and microscopic damage scores, immunohistochemical TNFα, CD3, Syk, and phospho-Syk expression, and tissue myeloperoxidase activity were found to be significantly lower in the colitis + fostamatinib group compared with the colitis group. "
10/01/2015 - "In our study we planned to research the efficacy of fostamatinib, a spleen tyrosine kinase inhibitor, on acetic acid-induced colitis. "
|5.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
07/01/2012 - "In chronic lymphocytic leukemia (CLL), Syk becomes activated by external signals from the tissue microenvironment, and was targeted in a first clinical trial with R788 (fostamatinib), a relatively nonspecific Syk inhibitor. "
08/01/2013 - "Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia."
04/01/2010 - "Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia."
03/01/2015 - "BCR signaling pathway inhibitors such as ibrutinib, idelalisib, and fostamatinib (respective inhibitors of Bruton's tyrosine kinase, PI3Kδ, and spleen tyrosine kinase) represent a significant therapeutic advance in B cell malignancies, including chronic lymphocytic leukemia (CLL). "
01/01/2010 - "The mTOR inhibitors temsirolimus and everolimus have demonstrated antitumor activity in all types of lymphoma, the Syk inhibitor fostamatinib has activity in diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and the PKC-β inhibitor enzastaurin is being used as consolidation therapy after remission in diffuse large B-cell lymphoma. "
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Inosine Triphosphate (ITP)
|5.||Interleukin-18 (Interleukin 18)
|6.||Acetic Acid (Vinegar)
|7.||Interleukin-6 (Interleukin 6)
|8.||Interleukin-1 (Interleukin 1)
|1.||Heterologous Transplantation (Xenotransplantation)